GlassScriptPhysician profile
Christopher A Cronsell
NPI 1831212109
$352,838.72
in general payments reported to CMS, 2019-2025
38 companies · $46K in 2025
The $46K reported for 2025 was more than what 99% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $27K · 2021: $84K · 2022: $62K · 2023: $60K · 2024: $49K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $88K · Consulting Fee: $35K · Honoraria: $15K · Travel and Lodging: $11K · Food and Beverage: $6,145 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $88,150.00 |
| Consulting Fee | $34,650.00 |
| Honoraria | $15,000.00 |
| Travel and Lodging | $10,969.32 |
| Food and Beverage | $6,145.42 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $150,556.92 | 2019-2022 | |
| Abbvie INC. | $146,773.66 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Piramal Critical Care | $48,859.37 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $1,218.10 | 2019-2025 | |
| Pacira Pharmaceuticals Incorporated | $950.61 | 2024 | Zilretta |
| Genentech USA, INC. | $634.52 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Ipsen Biopharmaceuticals, INC | $513.73 | 2022-2025 | Dysport |
| Lundbeck LLC | $437.66 | 2023-2025 | Vyepti |
| Biogen, INC. | $328.02 | 2020-2025 | Aduhelm, Leqembi |
| Merz Pharmaceuticals, LLC | $325.83 | 2023-2025 | Xeomin, Ampyra |
| Tg Therapeutics, INC. | $260.62 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $239.79 | 2019-2023 | Truxima |
| Celgene Corporation | $237.31 | 2020-2025 | Zeposia |
| Pfizer INC. | $212.42 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $178.45 | 2020-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $147.51 | 2024 | Daxxify |
| Alexion Pharmaceuticals, INC. | $136.68 | 2019-2023 | Ultomiris |
| Amgen INC. | $96.42 | 2022-2025 | Uplizna |
| Grifols USA, LLC | $76.62 | 2022-2025 | Gamunex-C, Xembify |
| US Oncology Corporate, INC. | $67.10 | 2021 | |
| Lilly USA, LLC | $60.94 | 2024-2025 | Reyvow, Emgality |
| Microtransponder, INC. | $57.00 | 2024 | |
| Genzyme Corporation | $51.95 | 2019-2024 | |
| Axsome Therapeutics, INC. | $45.34 | 2025 | Symbravo |
| Biohaven Pharmaceuticals, INC. | $39.83 | 2021 | |
| Octapharma USA, INC. | $37.67 | 2024 | Octagam Immune Globulin (Human) |
| Ucb, INC. | $34.36 | 2024 | Rystiggo |
| Acorda Therapeutics, INC | $33.69 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.20 | 2022 | |
| Vanda Pharmaceuticals INC. | $28.12 | 2025 | Ponvory |
| Emd Serono, INC. | $27.59 | 2019 | |
| Argenx US, INC. | $25.01 | 2025 | Vyvgart Hytrulo |
| Eisai INC. | $23.83 | 2023 | |
| Alnylam Pharmaceuticals INC. | $23.71 | 2022 | |
| Horizon Therapeutics Plc | $23.26 | 2022 | |
| Ani Pharmaceuticals, INC. | $22.50 | 2024 | Purified Cortrophin Gel |
| Amneal Pharmaceuticals LLC | $19.38 | 2023 | Lyvispah |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Cronsell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.